

Acknowledgment. This work was supported by the National Institutes of Health (Grant no. GM-28965).


Supplementary Material Available: Experimental procedures and full characterization for all compounds reported in this communication (12 pages). Ordering information is given on any current masthead page.

A Convergent, Enantiospecific Total Synthesis of the Novel Cyclodepsipeptide (+)-Jasplakinolide (Jaspamide)

Paul A. Grieco,* Yung Son Hon, and Arturo Perez-Medrano¹


Department of Chemistry, Indiana University
Bloomington, Indiana 47405
Received October 13, 1987

Jasplakinolide (**1**),² a novel cyclodepsipeptide isolated from a soft-bodied sponge, *Jaspis* sp., contains a new amino acid, 2-




bromoabrine, possessing the unnatural D configuration and the rare amino acid (*R*)- β -tyrosine.³ The potent insecticidal, antifungal, and anthelmintic properties² of jasplakinolide have been responsible for considerable synthetic activity in both industrial and academic laboratories. We wish to record the first total synthesis of (+)-jasplakinolide. The approach detailed below is both highly convergent and enantiospecific.

Our strategy for elaboration of jasplakinolide centered around the coupling of dipeptide **2** with the L-alanine derived acyclic fragment **3**. Construction of dipeptide **2** necessitated prior development of synthetic routes to the unnatural amino acids, (*R*)- β -tyrosine and D-bromoabrine.




Scheme I. Synthesis of the C(4)-C(11) Fragment 19^a




^a(a) NaHCO₃, I₂, H₂O, MeOH; (b) LiAlH₄, Et₂O, 0 °C; (c) *t*-BuMe₂SiCl, DMAP, Et₃N, CH₂Cl₂; (d) MOMCl, *i*-Pr₃NEt, CH₂Cl₂, 0 °C → room temperature; (e) Bu₄NF, THF; (f) (COCl)₂, DMSO, Et₃N, CH₂Cl₂, -78 °C; (g) isopropenylmagnesium bromide, THF, -78 °C; (h) CH₃C(OEt)₃, propionic acid (catalyst), 120 °C, 3 h; (i) KOH, MeOH, H₂O; (j) *t*-BuCOCl, Et₃N, Et₂O; (k) lithio-(*S*)-4-isopropyl-2-oxazolidinone, THF, -78 °C; (l) NaN(TMS)₂, THF, -78 °C, MeI; (m) KOH, MeOH, H₂O; (n) (PyS)₂, Ph₃P, CH₂Cl₂.

Our initial efforts were focused on the preparation of *N*^α-*t*-BOC-D-bromoabrine (**9**). Sequential treatment of a 0.2 M solution of commercially available *N*^α-*t*-BOC-D-tryptophan (**5**) in tetra-



hydrofuran at -78 °C with 3.0 equiv of sodium hexamethyldisilazide and 1.0 equiv of *tert*-butyldimethylchlorosilane provided in near quantitative yield *N*^α-*t*-BOC-*N*¹-*tert*-butyldimethylsilyl-D-tryptophan (**6**), [α]_D -21.2° (*c* 1.70, CHCl₃). Simultaneous *N*- and *O*-methylation (NaH, xsMeI, THF-DMF, 10:1, 60 °C) of **6** gave rise in ca. 80% yield to **7**, [α]_D +39.0° (*c* 1.27, CHCl₃), which upon exposure (0 °C → 25 °C, 3 h) to 2.0 equiv of pyridinium bromide perbromide in ether-chloroform, 1:1, afforded directly 2'-bromo-*N*^α-*t*-BOC-D-abrine methyl ester (**8**), [α]_D +69.4° (*c* 1.14, CHCl₃), in 50% yield. Saponification (1 N




NaOH, H₂O-THF, 1:1) of **8** gives rise to a 96% yield of 2'-bromo-*N*^α-*t*-BOC-D-abrine (**9**), [α]_D +83.4° (*c* 1.28, MeOH). The formation of **9** proceeds without any racemization as evidenced by the proton NMR of 2'-bromo-D-abrine methyl ester in the presence of tris[3-[(heptafluoropropyl)hydroxymethylene]-(+)-camphorato]europium(III).

Preparation of the (*R*)- β -tyrosine derivative **13** commenced with commercially available L-4-hydroxyphenylglycine. *tert*-Butyloxycarbonylation (BOC-ON, Et₃N, H₂O-dioxane, 1:1)⁵ of L-4-hydroxyphenylglycine followed by silylation [(a) *t*-Bu(Me)₂SiCl, imidazole, DMF; (b) K₂CO₃, MeOH, H₂O] provided **10**, [α]_D +81.0° (*c* 1.34, CHCl₃) in 98% overall yield. *N*-*t*-BOC amino acid **10** was converted (ClCOOEt, Et₃N, Et₂O) into a mixed anhydride which upon treatment with ethereal diazomethane generated diazoketone **11** in 81% yield. Wolff rearrangement of **11** proceeded smoothly in the presence of silver benzoate and triethylamine in *tert*-butyl alcohol giving rise to **12**, [α]_D +22.6°


(1) Berlex Predoctoral Fellow, 1987-1988.
(2) (a) Crews, P.; Manes, L. V.; Bohler, M. *Tetrahedron Lett.* **1986**, 27, 2797. (b) Zabriskie, T. M.; Klocke, J. A.; Ireland, C. M.; Marcus, A. H.; Molinski, T. F.; Faulkner, D. J.; Xu, C.; Clardy, J. C. *J. Am. Chem. Soc.* **1986**, 108, 3123.
(3) Natural (*S*)- β -tyrosine was first found in two peptide antibiotics, edeine A and edeine B, obtained from cultures of *Bacillus brevis* Vm 4.⁴

(4) Wojciechowska, H.; Ciaskowski, J.; Chmara, H.; Borowski, E. *Experientia* **1972**, 28, 1423.

(5) Itoh, M.; Hagiwara, D.; Kamiya, T. *Tetrahedron Lett.* **1975**, 4393.



Coupling (DCC, HBT, THF) of the (*R*)- β -tyrosine derivative **13** with amino acid **9** provided the fully protected dipeptide **14**,



Completion of the total synthesis of jasplakinolide required coupling of dipeptide **2** with the C(1)–C(11) segment **3**, which was accomplished with 1.05 equiv of DCC and 1.0 equiv of HBT¹¹ in tetrahydrofuran. The coupled product **4**, [α]_D +24.4° (c 1.09, CHCl₃), was obtained in ca. 50% yield. Conversion of **4** into **1** was realized by the following sequence: (1) cleavage (82%) of the *tert*-butyl ester employing TBDMSOTf (3.0 equiv)/2,6-

Supplementary Material Available: Spectral and analytical data for key intermediates **4**, **9**, and **14** and the acid precursor to **19** (1 page). Ordering information is given on any current masthead page.

(12) Boden, E. P.; Keck, G. E. *J. Org. Chem.* **1985**, *50*, 2394.

Bis(trimethylstannyl)benzopinacolate-Mediated Intermolecular Free-Radical Carbon–Carbon Bond-Forming Reactions: A New One-Carbon Homologation

Department of Chemistry, The Ohio State University
Columbus, Ohio 43210

Received August 26, 1987

We began by examining the reactions shown below. Thus, treatment of 1 equiv of iodocyclohexane with tri-*n*-butyltin hydride


[†] Alfred P. Sloan Fellow, 1983–1987.

(1) For an overview of intermolecular free-radical addition reactions in organic synthesis, see: Giese, B. *Radicals in Organic Synthesis: Formation of Carbon-Carbon Bonds*; Baldwin, J. E., Ed.; Pergamon Press: New York, 1986.

(2) Stork, G.; Sher, P. M. *J. Am. Chem. Soc.* **1983**, *105*, 6765. Stork, G.; Sher, P. M. *J. Am. Chem. Soc.* **1986**, *108*, 303.

(3) Corey, E. J.; Pyne, S. G. *Tetrahedron Lett.* **1983**, 2821.

(4) (a) Prior to the onset of this study, we demonstrated that i could be converted to a 1:1 mixture of diastereomeric perhydroindans ii (unpublished results with Dr. Balan Chenera). (b) Also, see: Barlett, P. A.; McLaren, K. L.; Ting, P. C. *J. Am. Chem. Soc.* **1988**, following paper in this issue.



(6) Cf. Ohfuné, Y.; Sakaitani, M. *Tetrahedron Lett.* **1985**, 26, 5543.

(7) Cf. Corey, E. J.; Hase, T. *Tetrahedron Lett.* **1979**, 335.

(8) Evans, D. A.; Ennis, M. D.; Mathre, D. J. *J. Am. Chem. Soc.* **1982**, *104*, 1737.

(9) Mukaiyama, T.; Matsueda, R.; Suzuki, M. *Tetrahedron Lett.* **1970**, 1901.

(10) Venkateswaran, P. S.; Bardos, T. J. *J. Org. Chem.* **1967**, *32*, 1256.

(11) König, W.; Geiger, R. *Chem. Ber.* **1970**, *103*, 788.